Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07656324
Recruiting Observational

Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

NCT07656324 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Observational
Started
2025-01-17
Last updated
2026-06-18

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

No Interventions

No Interventions: No Interventions

Study summary

This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Male or female, aged 18 years or older. 2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form. 3. Malignant tumor confirmed histologically or cytologically. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study. 3. Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma). 4. Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses. 5. Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure. 6. Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.

Primary outcome measure(s)

  • The incidence of cancer-related fatigue (CRF) in tumor patients. — Baseline
    The incidence of cancer-related fatigue (CRF) in tumor patients.

Trial sites (1)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center Shanghai Shanghai Municipality Recruiting

More Fudan University trials in China

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases Recruiting
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment Recruiting
Selective Neck Dissection Versus Modified Neck Dissection in PTC Recruiting
MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer Active, not recruiting
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma Recruiting

Other trials for the same condition

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Enrolling by invitation
A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke Starting soon
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors Recruiting
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer Recruiting
The Jinling Cohort Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07656324 on ClinicalTrials.gov ↗ ← All trials in China